Open AccessPulmonary arterial hypertension: challenges and achievements 2021
Author(s) -
Е. А. Резухина,
T. V. Martynyuk,
З. С. Валиева,
В. В. Грамович,
И Е Чазова
Publication year - 2022
Publication title -
evrazijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2305-0748
pISSN - 2225-1685
DOI - 10.38109/2225-1685-2022-1-80-89
Subject(s) - medicine , risk stratification , pulmonary hypertension , intensive care medicine , pandemic , clinical trial , covid-19 , clinical practice , cardiology , family medicine , disease , infectious disease (medical specialty)
Symposium dedicated to pulmonary arterial hypertension took place at the 9th Russian Congress on Pulmonary hypertension on December 14, 2021. In this review key points from Chazova I.E., Martynyuk T.V., Valieva Z.S., Gramovich V.V.`s reports are presented, in which information about PAH treatment goals achievement, COVID-19 pandemic challenges impact on routine clinical practice is demonstrated. In this review current situation in pulmonary arterial hypertension treatment goals and regular risk stratification importance are observed, based on the latest clinical trials combined specific therapy including selective prostacyclin receptor agonist selexipag is demonstrated. special attention is paid to pulmonary hypertension patients’ treatment during COVID-19 pandemic, regular risk stratification necessity is mentioned including remote patient monitoring in order to perform timely escalation in PAH-specific treatment in order to achieve low-risk status and to improve the prognosis of PAH patients.